Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Beam Therapeutics (BEAM) Stock Price & Analysis

2,358 Followers

BEAM Stock Chart & Stats

$26.41$0.54(2.09%)
At close: 4:00 PM EST
$22.5$25$27.5$30Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$25.84 - $26.77
52-Week Range
$20.23 - $38.26
Previous Close
$25.87
Volume
N/A
Average Volume (3M)
1.86M
Market Cap
$2.73B
Enterprise Value
$1.76B
Total Cash (Recent Filing)
$1.04B
Total Debt (Recent Filing)
$243.87M
Price to Earnings (P/E)
―
Beta
2.28
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
-1.25
Last Dividend Ex-Date
Nov 04, 2013
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Platform Progress

Beam is advancing multiple programs while generating early clinical evidence for its in vivo platform. Progress across distinct candidates can improve the value of its base-editing capabilities, support knowledge transfer between programs, and create several future paths toward commercial medicines.

Manageable Leverage

Lower leverage and declining total debt provide Beam with a steadier financial structure than its operating losses alone would suggest. A sizable equity base and reduced debt burden may preserve flexibility to fund research, clinical development, and partnerships over the next several quarters.

Improved Financial Trend

Although Beam remains unprofitable, the material improvement from 2024 indicates that financial performance has not been uniformly deteriorating. Cost and mix normalization could provide a better base for future operating leverage if clinical progress and collaboration activity translate into stronger revenue.

Bears Say

Persistent Cash Burn

Large and recurring operating and free-cash-flow deficits show that Beam’s research and development model continues to consume substantial cash. Persistent burn can reduce funding flexibility and make future progress increasingly dependent on available capital, collaboration inflows, or additional financing.

Unprofitable Revenue Base

Beam has not yet established a profitable operating base: revenue declined on a trailing basis while losses remained substantial and margins deeply negative. This limits internally generated funding for the pipeline and means future financial improvement depends heavily on successful development and revenue growth.

Collaboration-Driven Revenue

The current business model relies mainly on partnership-related upfronts, research funding, milestones, and potential royalties rather than recurring product sales. This can make revenue timing dependent on agreement terms and development achievements, leaving the company without an established commercial product base.

Beam Therapeutics News

BEAM FAQ

What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $20.23 and its highest was $38.26 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $2.73B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 113 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on Nov 03, 2026. The company reported -$1.28 earnings per share for the quarter, missing the consensus estimate of -$1.155 by -$0.125.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics pays a Quarterly dividend of $0.225 which represents an annual dividend yield of ―. See more information on Beam Therapeutics dividends here
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.25.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 103,495,640 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1.28 in its last earnings report, missing expectations of -$1.155. Following the earnings report the stock price went up 1.778%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Hedge funds hold Beam Therapeutics shares: the largest hedge-fund position in Beam Therapeutics is 70,130,379 shares, and hedge funds decreased their holdings by 1.1M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology